Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL519725 | 0.86 | JAK2 (0.42) | JAK2PTK2KCNH2IDO1JAK3 | |
| SCHEMBL519867 | 0.77 | JAK2 (0.46) | JAK2PTK2KCNH2IDO1JAK3 | |
| SCHEMBL520457 | 0.77 | IDO1 (0.47) | JAK2PTK2KCNH2IDO1JAK3 | |
| SCHEMBL520267 | 0.75 | JAK2 (0.42) | JAK2PTK2KCNH2IDO1JAK3 | |
| SCHEMBL521079 | 0.75 | JAK2 (0.45) | JAK2PTK2KCNH2IDO1JAK3 | |
| SCHEMBL520240 | 0.74 | KCNH2 (0.48) | JAK2PTK2KCNH2JAK3FYN | |
| SCHEMBL520412 | 0.72 | CDK1 (0.41) | JAK2PTK2KCNH2PTGS2MAOB | |
| SCHEMBL526558 | 0.69 | JAK2 (0.32) | JAK2PTK2 | |
| SCHEMBL520662 | 0.69 | INSR (0.44) | JAK2PTK2FYN | |
| SCHEMBL519735 | 0.67 | KCNH2 (0.40) | KCNH2IDO1PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | JAK2 1/4885PTK2 592/4885KCNH2 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.